SITAGLIPTIN
Clinical safety rating: safe
Animal studies have demonstrated safety
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases active incretin (GLP-1 and GIP) levels by preventing their degradation, thereby enhancing insulin secretion and suppressing glucagon release in a glucose-dependent manner.
| Metabolism | Primarily excreted unchanged in urine via active tubular secretion; minor metabolism via CYP3A4 and CYP2C8 to inactive metabolites. |
| Excretion | Renal: ~87% unchanged in urine (active tubular secretion); fecal: <13% (metabolites). |
| Half-life | 12.4 hours; supports once-daily dosing with effect ≥24 h due to sustained DPP-4 inhibition. |
| Protein binding | 38% (primarily albumin). |
| Volume of Distribution | ~0.2 L/kg (≈198 L total, indicates distribution into total body water). |
| Bioavailability | 87% (oral). |
| Onset of Action | Oral: ~1-2 hours (peak DPP-4 inhibition >80% by 2 h, glucose-lowering effect begins within 1-2 h). |
| Duration of Action | 24 hours (DPP-4 inhibition >80% at 12 h, ≈50% at 24 h; glucose-lowering effect persists 24 h). |
100 mg orally once daily.
| Dosage form | TABLET |
| Renal impairment | eGFR ≥30 mL/min/1.73 m²: no adjustment. eGFR 25-30 mL/min/1.73 m²: 50 mg orally once daily. eGFR <25 mL/min/1.73 m² or ESRD (on dialysis): 25 mg orally once daily. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh class A or B). Not studied in severe hepatic impairment (Child-Pugh class C); use with caution. |
| Pediatric use | Not approved for use in pediatric patients <18 years of age. |
| Geriatric use | No dose adjustment based solely on age; however, renal function should be assessed as elderly patients are more likely to have decreased renal function, and dose adjustments per renal function are recommended. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions May cause hypersensitivity reactions including anaphylaxis.
| Breastfeeding | Sitagliptin is excreted in rat milk. Human data: no studies; M/P ratio unknown. Caution advised; avoid breastfeeding due to potential infant hypoglycemia and unknown long-term effects. |
| Teratogenic Risk | Sitagliptin is FDA Pregnancy Category B. Animal studies show no teratogenicity at 30 times human exposure. No adequate human studies in pregnancy; first trimester data limited. Risk cannot be excluded; use only if clearly needed. Second/third trimester: no reports of structural defects. |
■ FDA Black Box Warning
None.
| Common Effects | Nasopharyngitis |
| Serious Effects |
["Hypersensitivity to sitagliptin or any component of the formulation (e.g., anaphylaxis, angioedema)","Type 1 diabetes mellitus","Diabetic ketoacidosis"]
| Precautions | ["Acute pancreatitis (monitor for symptoms; discontinue if suspected)","Hypoglycemia when used with sulfonylureas or insulin (may require dose reduction of those agents)","Severe and disabling arthralgia (consider alternative DPP-4 inhibitor or other antidiabetic therapy if joint pain persists)","Bullous pemphigoid (monitor for blisters/erosions; discontinue if suspected)","Acute kidney injury (dose adjustment required in renal impairment; monitor renal function)","Postmarketing reports of heart failure (use with caution in patients with risk factors for heart failure)"] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood glucose and HbA1c. In pregnancy, monitor fetal growth via ultrasound. Assess for maternal hypoglycemia. No specific fetal toxicity monitoring required. |
| Fertility Effects | Sitagliptin did not impair fertility in animal studies at high doses. No human fertility data available. Theoretical risk of hormonal changes, but no direct evidence of adverse reproductive effects. |